Here is a short summary of my interpretation of al
Post# of 148183
- Drug works as advertised, i.e. rapidly reduces inflammation in the lungs of ARDS affected patients
- This is a game changer as it can be the difference between life and death
- It appears that 10 out of 10 patients who were administered Leronlimab in the ICU responded positively
- Unclear as to how many of these 10 patients in the ICU were on respirators? We know at least 2 were extubated for sure. Could be more if they were on respirators but unclear ...
- The reporter, not NP, said all 10 patients were out of the ICU. Seems fast but I guess if they recovered enough other patients maybe worse off?
Now, some other thoughts:
- Based on everything I have read, there is still no “new” proven safe therapeutic drug. Many being developed but at least 12-18 months before commercial use
- Vaccines are in the same boat, 12-18 months
- Of the existing drugs that maybe partially effective and have proven safety records, NONE have the type of MOA that can save a patient in ARDS mode aside from Leronlimab (this claim is to be finalized in the next 3-4 weeks with FDA approved controlled tests).
- Testing now extended to early and moderate corona virus cases. Again results in 3-4 weeks. High likelihood of the same MOA will result in positive outcomes.
- These short time frames to potential commercial success and revenues are unheard of!
Lastly,
- This MOA has now validated Leronlimab’s potential for so many immunological related illnesses that NP has alluded to but no time or money to test
- And as others have documented, the enormous progress Cytodyn has had in HIV, cancer, etc... will now get so much more visibility in both the medical world and in the eyes of the general public!
Only good days ahead!!!